Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Chemotherapy and SBRT for Neoadjuvant Treatment of Limited-Stage Small Cell Lung Cancer
NCT06562920Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Countries
- 1
- Sponsor
- Zhejiang Cancer Hospital
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- adebrelimab
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Pathological Complete Response and Safety and Tolerability. Started Jul 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Neoadjuvant Adebrelimab + Chemo + SBRT
Adebrelimab combined with chemotherapy and concurrent SBRT followed by surgery
03
Who it enrols
Patients with resectable limited-stage small cell lung cancer (T1-3N0-1M0) who have not received prior treatment, with good performance status and organ function.
04
Endpoints
Primary
Pathological Complete Response
Safety and Tolerability
Secondary
Major Pathological Response
Event-Free Survival
Objective Response Rate
Overall Survival
Tumor Efficacy Markers
Beyond the preview
Go deeper on NCT06562920.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562920.